Literature DB >> 28063378

Overexpression of PTP4A3 in ETV6-RUNX1 acute lymphoblastic leukemia.

Toni Grönroos1, Susanna Teppo2, Juha Mehtonen3, Saara Laukkanen2, Thomas Liuksiala4, Matti Nykter5, Merja Heinäniemi3, Olli Lohi2.   

Abstract

Cell signalling, which is often derailed in cancer, is a network of multiple interconnected pathways with numerous feedback mechanisms. Dynamics of cell signalling is intimately regulated by addition and removal of phosphate groups by kinases and phosphatases. We examined expression of members of the PTP4A family of phosphatases across acute leukemias. While expression of PTP4A1 and PTP4A2 remained relatively unchanged across diseases, PTP4A3 showed marked overexpression in ETV6-RUNX1 and BCR-ABL1 subtypes of precursor B cell acute lymphoblastic leukemia. We show that PTP4A3 is regulated by the ETV6-RUNX1 fusion, but noticed no marked impact on cell viability either after PTP4A3 silencing or treatment with a PTP4A3 inhibitor. Regulation of PTP4A3 expression is altered in specific subgroups of acute leukemias and this is likely brought about by expression of the aberrant fusion genes.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ETV6-RUNX1; Leukemia; PTP4A3

Mesh:

Substances:

Year:  2016        PMID: 28063378     DOI: 10.1016/j.leukres.2016.12.005

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  4 in total

1.  Combination of ERK2 and STAT3 Inhibitors Promotes Anticancer Effects on Acute Lymphoblastic Leukemia Cells.

Authors:  Ewa Jasek-Gajda; Halina Jurkowska; MaŁgorzata JasiŃska; Jan A Litwin; Grzegorz J Lis
Journal:  Cancer Genomics Proteomics       Date:  2020 Sep-Oct       Impact factor: 4.069

2.  Phosphatase of regenerating liver-3 is expressed in acute lymphoblastic leukemia and mediates leukemic cell adhesion, migration and drug resistance.

Authors:  Magnus A Hjort; Pegah Abdollahi; Esten N Vandsemb; Mona H Fenstad; Bendik Lund; Tobias S Slørdahl; Magne Børset; Torstein B Rø
Journal:  Oncotarget       Date:  2017-12-13

Review 3.  Pathogenesis of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia and mechanisms underlying its relapse.

Authors:  Congcong Sun; Lixian Chang; Xiaofan Zhu
Journal:  Oncotarget       Date:  2017-05-23

4.  A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/β-catenin pathways for treatment of AML with high PRL-3 phosphatase.

Authors:  Jianbiao Zhou; Sabrina Hui-Min Toh; Zit-Liang Chan; Jessie Yiying Quah; Jing-Yuan Chooi; Tuan Zea Tan; Phyllis S Y Chong; Qi Zeng; Wee-Joo Chng
Journal:  J Hematol Oncol       Date:  2018-03-07       Impact factor: 17.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.